Grufity logoGrufity logo

Codexis Inc Stock Research

CDXS

3.96USD+0.15(+3.94%)Market Closed

Market Summary

USD3.96+0.15
Market Closed
3.94%

CDXS Alerts

CDXS Stock Price

CDXS RSI Chart

CDXS Valuation

Market Cap

260.6M

Price/Earnings (Trailing)

-7.76

Price/Sales (Trailing)

1.88

EV/EBITDA

-5.26

Price/Free Cashflow

87.54

CDXS Price/Sales (Trailing)

CDXS Profitability

EBT Margin

-24.04%

Return on Equity

-23.2%

Return on Assets

-13.42%

Free Cashflow Yield

1.14%

CDXS Fundamentals

CDXS Revenue

Revenue (TTM)

138.6M

Revenue Y/Y

23.97%

Revenue Q/Q

-11.88%

CDXS Earnings

Earnings (TTM)

-33.6M

Earnings Y/Y

-23.69%

Earnings Q/Q

-26.14%

Price Action

52 Week Range

3.7922.22
(Low)(High)

Last 7 days

-3.9%

Last 30 days

-27.2%

Last 90 days

-10.6%

Trailing 12 Months

-80.4%

CDXS Financial Health

Current Ratio

3.32

CDXS Investor Care

Shares Dilution (1Y)

1.08%

Diluted EPS (TTM)

-0.51

Peers (Alternatives to Codexis)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
38.9B
6.8B
-8.16% -1.51%
30.98
5.67
8.37% 3.64%
34.5B
4.6B
7.77% -35.67%
-7.84
7.53
1.28% -677.95%
32.4B
3.9B
0.40% 7.77%
37.17
8.27
5.43% 13.46%
11.4B
1.1B
-1.86% -32.35%
43.34
10.14
8.77% 24.82%
MID-CAP
9.1B
801.5M
-8.02% -7.39%
48.92
11.35
19.54% 44.95%
SMALL-CAP
2.1B
128.3M
2.84% -4.86%
-6.78
16.59
-1.69% -73.40%
1.1B
185.3M
-9.20% -39.56%
-5.71
6.17
20.06% 3.42%
417.7M
127.3M
-10.60% -72.39%
-2.62
3.28
-12.28% -38.43%
404.9M
105.5M
-8.66% -62.15%
-4.19
3.84
-4.55% -67.63%
323.9M
27.8M
-21.01% -54.58%
-2.44
11.65
54.62% -83.06%
260.6M
138.6M
-27.21% -80.41%
-7.76
1.88
32.30% -57.86%
128.8M
113.3M
4.79% -47.51%
-13.53
1.14
-4.68% -3204.17%
119.3M
72.0M
-6.98% -36.25%
-7.23
1.66
6.82% 39.11%
56.3M
54.1M
-3.61% -51.28%
521
1.04
21.80% -72.38%

Financials for Codexis

Income Statement (Last 12 Months)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue4.4%138,590,000132,717,000135,016,000122,063,000104,754,000
  S&GA Expenses1.1%52,172,00051,583,00051,491,00053,630,00049,323,000
  R&D Expenses4.3%80,099,00076,767,00070,111,00063,848,00055,919,000
EBITDA-7.1%-27,880,000-26,024,000-14,330,000-16,687,000-
EBITDA Margin-2.6%-0.20-0.20-0.11-0.14-
Earnings Before Taxes-7.5%-33,316,000-30,985,000-18,647,000-20,372,000-21,090,000
EBT Margin-3.0%-0.24-0.23-0.14-0.17-
Interest Expenses13.3%34,00030,00023,00016,00014,000
Net Income-7.7%-33,592,000-31,178,000-18,942,000-20,567,000-21,279,000
Net Income Margin-3.2%-0.24-0.23-0.14-0.17-
Free Cahsflow143.8%2,977,000-6,793,000-29,413,000-35,380,000-
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets6.4%250235235235246
  Current Assets11.6%163146145145162
    Cash Equivalents4.9%11410990.0094.00117
  Inventory25.0%2.002.002.002.001.00
  Net PPE-3.0%23.0023.0024.0023.0021.00
  Goodwill-1.3%3.003.003.003.003.00
Liabilities30.1%10681.0076.0077.0082.00
  Current Liabilities53.8%49.0032.0030.0029.0033.00
Shareholder's Equity-6.1%145154159159164
  Retained Earnings-3.1%-421-408-398-396-387
  Additional Paid-In Capital0.6%566563558555552
Accumulated Depreciation3.2%39.0038.0037.0036.00-
Shares Outstanding0.3%66.0066.0065.0065.0065.00
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations60.6%11.007.00-12.90-19.01-14.27
  Share Based Compensation-0.8%15.0015.0013.0013.0012.00
Cashflow From Investing28.9%-13.58-19.09-28.78-28.97-21.42
Cashflow From Financing-138.0%-0.572.002.002.004.00

Risks for CDXS

What is the probability of a big loss on CDXS?

99.2%


Probability that Codexis stock will be more than 20% underwater in next one year

69.2%


Probability that Codexis stock will be more than 30% underwater in next one year.

53.9%


Probability that Codexis stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does CDXS drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Codexis was unfortunately bought at previous high price.

Drawdowns

Returns for CDXS

Cumulative Returns on CDXS

5.4%


10-Year Cumulative Returns

3.2%


7-Year Cumulative Returns

-18.5%


5-Year Cumulative Returns

-26.5%


3-Year Cumulative Returns

What are the long-term rolling returns for CDXS?

FIve years rolling returns for Codexis.

Annualized Returns

Which funds bought or sold CDXS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-10
BAILLIE GIFFORD & CO
reduced
-12.13
-13,891,800
28,941,200
0.03%
2023-03-06
Rockefeller Capital Management L.P.
reduced
-9.09
-2,000
4,000
-%
2023-02-28
Voya Investment Management LLC
unchanged
-
-33,577
112,423
-%
2023-02-21
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
reduced
-99.97
-19,995
5.00
-%
2023-02-21
MACQUARIE GROUP LTD
sold off
-
-4,000
-
-%
2023-02-16
WHITE PINE CAPITAL LLC
added
53.4
155,988
1,023,990
0.40%
2023-02-15
MetLife Investment Management, LLC
unchanged
-
-46,392
153,608
-%
2023-02-15
JANE STREET GROUP, LLC
sold off
-100
-63,000
-
-%
2023-02-15
ALLIANCEBERNSTEIN L.P.
added
23.88
-17,582
355,418
-%
2023-02-15
HOWE & RUSLING INC
sold off
-100
-30,000
-
-%

1–10 of 49

Latest Funds Activity

Are funds buying CDXS calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own CDXS
No. of Funds

Codexis News

Defense World

Century Aluminum (NASDAQ:CENX) Earns Sell Rating from ....

Defense World,
3 days ago

Securities.io

Simply Wall St

Armenian Reporter

Laredo Morning Times

Codexis: Q4 Earnings Snapshot.

Laredo Morning Times,
28 days ago

GuruFocus.com

Codexis Announces New Employme.

GuruFocus.com,
35 days ago

Schedule 13G FIlings of Codexis

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
nantahala capital management, llc
6.8%
4,487,782
SC 13G/A
Feb 14, 2023
casdin capital, llc
0%
0
SC 13G/A
Feb 10, 2023
ark investment management llc
6.00%
3,941,985
SC 13G/A
Feb 09, 2023
vanguard group inc
5.54%
3,642,208
SC 13G/A
Jan 24, 2023
blackrock inc.
9.4%
6,154,933
SC 13G/A
Jan 18, 2023
baillie gifford & co
9.46%
6,210,551
SC 13G/A
Feb 09, 2022
vanguard group inc
5.24%
3,400,490
SC 13G
Feb 09, 2022
ark investment management llc
5.00%
3,244,040
SC 13G/A
Feb 03, 2022
blackrock inc.
7.9%
5,144,949
SC 13G/A
Jan 12, 2022
baillie gifford & co
11.07%
7,182,402
SC 13G/A

CDXS Fair Value

Codexis fair value in different scenarios

The table shows the Fair Value estimates for Codexis for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

0.76

-80.81%

1.07

-72.98%

1.68

-57.58%

3.15

-20.45%

4.97

25.51%
Current Inflation

0.74

-81.31%

1.02

-74.24%

1.55

-60.86%

2.81

-29.04%

4.38

10.61%
Very High Inflation

0.71

-82.07%

0.95

-76.01%

1.39

-64.90%

2.42

-38.89%

3.69

-6.82%

Historical Codexis Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Codexis

View All Filings
Date Filed Form Type Document
Mar 17, 2023
4
Insider Trading
Mar 09, 2023
4
Insider Trading
Mar 09, 2023
4
Insider Trading
Mar 09, 2023
4
Insider Trading
Feb 28, 2023
POS AM
POS AM
Feb 27, 2023
10-K
Annual Report
Feb 27, 2023
4
Insider Trading
Feb 27, 2023
POSASR
POSASR
Feb 23, 2023
8-K
Current Report
Feb 21, 2023
4
Insider Trading

Latest Insider Trading transactions for CDXS

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-16
NICOLS JOHN J
sold
-146,681
4.1071
-35,714
-
2023-03-16
NICOLS JOHN J
acquired
70,356
1.97
35,714
-
2023-03-15
NICOLS JOHN J
sold
-146,131
4.0917
-35,714
-
2023-03-15
NICOLS JOHN J
acquired
70,356
1.97
35,714
-
2023-03-08
DILLY STEPHEN GEORGE
sold
-122,931
4.5552
-26,987
see remarks
2023-03-08
Norrett Kevin
sold
-37,616
4.5552
-8,258
chief operating officer
2023-03-08
Fitzgerald Margaret Nell
sold
-35,011
4.5552
-7,686
see remarks
2023-03-07
Norrett Kevin
sold
-39,564
4.6027
-8,596
chief operating officer
2023-03-07
Fitzgerald Margaret Nell
sold
-36,821
4.6027
-8,000
see remarks
2023-03-07
DILLY STEPHEN GEORGE
sold
-129,281
4.6027
-28,088
see remarks

1–10 of 50

John J. Nicols
260
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

CDXS Income Statement

2022-12-31
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenues:   
Total revenues$ 138,590$ 104,754$ 69,056
Costs and operating expenses:   
Cost of product revenue38,03322,20913,742
Research and development80,09955,91944,185
Selling, general and administrative52,17249,32335,049
Restructuring charges3,16700
Total costs and operating expenses173,471127,45192,976
Income (loss) from operations(34,881)(22,697)(23,920)
Interest income1,441459405
Other income (expense), net ($208, $983 and $0 from a related party)1241,148(156)
Loss before income taxes(33,316)(21,090)(23,671)
Provision for income taxes276189339
Net loss$ (33,592)$ (21,279)$ (24,010)
Net loss per share, basic (in dollars per share)$ (0.51)$ (0.33)$ (0.40)
Net loss per share, diluted (in dollars per share)$ (0.51)$ (0.33)$ (0.40)
Weighted average common stock shares used in computing net loss per share, basic (in shares)65,34464,56859,360
Weighted average common stock shares used in computing net loss per share, diluted (in shares)65,34464,56859,360
Product revenue ($514, $0 and $0 from a related party)   
Revenues:   
Total revenues$ 116,676$ 70,657$ 30,220
Research and development revenue ($1,245, $1,955 and $900 from a related party)   
Revenues:   
Total revenues$ 21,914$ 34,097$ 38,836

CDXS Balance Sheet

2022-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 113,984$ 116,797
Restricted cash, current521579
Financial assets:  
Accounts receivable31,90424,953
Contract assets2,1164,557
Unbilled receivables7,0168,558
Total financial assets41,03638,068
Less: allowances(163)(416)
Total financial assets, net40,87337,652
Inventories2,0291,160
Prepaid expenses and other current assets5,4875,700
Total current assets162,894161,888
Restricted cash1,5211,519
Investment in non-marketable equity securities ($13,921 and $12,713 with a related party)20,51014,002
Right-of-use assets - Operating leases, net39,26344,095
Right-of-use assets - Finance leases, net017
Property and equipment, net22,61421,345
Goodwill3,2413,241
Other non-current assets350276
Total assets250,393246,383
Current liabilities:  
Accounts payable3,2462,995
Accrued compensation11,45311,119
Other accrued liabilities15,27912,578
Current portion of lease obligations - Operating leases5,3604,093
Deferred revenue ($0 and $245 to a related party)13,7282,586
Total current liabilities49,06633,371
Deferred revenue, net of current portion16,8813,749
Long-term lease obligations - Operating leases38,27843,561
Other long-term liabilities1,3711,311
Total liabilities105,59681,992
Commitments and contingencies (Note 13)
Stockholders’ equity:  
Preferred stock, $0.0001 par value per share; 5,000 shares authorized, none issued and outstanding00
Common stock, $0.0001 par value per share; 100,000 shares authorized; 65,811 and 65,109 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively66
Additional paid-in capital566,081552,083
Accumulated deficit(421,290)(387,698)
Total stockholders’ equity144,797164,391
Total liabilities and stockholders’ equity$ 250,393$ 246,383